home / stock / epgny / epgny short
Short Information | Epigenomics Ag S/Adr (OTCMKTS:EPGNY)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 8,523 |
Total Actual Volume | 12,048 |
Short Trends | |
---|---|
Cover Days | 5 |
Short Days | 13 |
No Change Days | 2 |
Averages | |
---|---|
Average Short Volume | 426 |
Average Short Percentage | 65.93% |
Is there a EPGNY Short Squeeze or Breakout about to happen?
See the EPGNY Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
09-15-2022 | $2.005 | $2.29 | $2.29 | $2.005 | 407 | 407 | 100% |
08-24-2022 | $0 | $2.8 | $0 | $0 | 10 | 10 | 100% |
03-07-2022 | $2.8 | $2.8 | $2.8 | $2.8 | 100 | 100 | 100% |
09-01-2021 | $7.55 | $7.55 | $7.55 | $7.55 | 100 | 100 | 100% |
05-06-2021 | $7.8 | $7.8 | $7.8 | $7.8 | 179 | 79 | 44.13% |
03-15-2021 | $13.77 | $13.77 | $13.77 | $13.77 | 252 | 252 | 100% |
02-17-2021 | $16.25 | $16.05 | $16.25 | $16.05 | 417 | 307 | 73.62% |
02-04-2021 | $17.41 | $17.41 | $17.41 | $17.41 | 331 | 131 | 39.58% |
01-25-2021 | $17.97 | $17.97 | $17.97 | $17.97 | 115 | 114 | 99.13% |
12-17-2020 | $17.28 | $15 | $17.28 | $15 | 1,206 | 105 | 8.71% |
12-02-2020 | $2.765 | $2.765 | $2.765 | $2.765 | 221 | 1 | 0.45% |
11-03-2020 | $2.66 | $2.67 | $2.67 | $2.42 | 300 | 200 | 66.67% |
10-28-2020 | $3.5 | $3.25 | $3.5 | $3.25 | 500 | 100 | 20% |
10-20-2020 | $4.44 | $4.88 | $4.88 | $4.44 | 1,580 | 1,100 | 69.62% |
10-16-2020 | $13.99 | $13.99 | $13.99 | $13.99 | 3,414 | 3,401 | 99.62% |
10-07-2020 | $14.95 | $14.95 | $14.95 | $14.95 | 200 | 200 | 100% |
09-21-2020 | $13.91 | $13.91 | $13.91 | $13.91 | 1,000 | 900 | 90% |
09-18-2020 | $15.56 | $15.56 | $15.56 | $15.56 | 1,006 | 1,006 | 100% |
08-26-2020 | $18.32 | $18.32 | $18.32 | $18.32 | 107 | 7 | 6.54% |
08-19-2020 | $18.7 | $18.7 | $18.7 | $18.7 | 603 | 3 | 0.5% |
News, Short Squeeze, Breakout and More Instantly...
Epigenomics Ag S/Adr Company Name:
EPGNY Stock Symbol:
OTCMKTS Market:
Under the primary base case analysis, annual m SEPT9 screening resulted in more Quality-adjusted-life-years gained (QALYG), CRC cases averted and CRC deaths averted than both annual FIT screening and Cologuard ® every three years, albeit at a higher colonoscopy referral rate ...
Dover, Delaware--(Newsfile Corp. - June 17, 2020) - Encode Ideas, L.P. Initiates Research on Epigenomics AG (Xetra: ECX.DE) (FSE: ECX) (OTC: EPGNF). The full research publication is available here and available on our website at www.encodelp.com . A summary follows: Encode Ideas, L.P., a h...
- Adherence rates and screening intervals recognized as decisive elements of successful screening strategies - BERLIN, Dec. 02, 2019 (GLOBE NEWSWIRE) -- Epigenomics AG (FSE: ECX, OTCQX: EPGNY; the “Company”), today reported on micro-simulation model results indicating th...